Download PDF
Journal of Pediatric Biochemistry 2015; 05(04): 139-145
DOI: 10.1055/s-0036-1572362
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Metaiodobenzylguanidine and Neuroblastoma

Julia Balaguer
1   Department of Pediatric Oncology, Hospital Universitario y Politécnico La Fe. Valencia, Spain
,
Jose Luis Loaiza
2   Department of Nuclear Medicine, Hospital Universitario y Politécnico La Fe. Valencia, Spain
,
Andrea Di Cataldo
3   Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy
,
Pilar Bello
2   Department of Nuclear Medicine, Hospital Universitario y Politécnico La Fe. Valencia, Spain
,
Adela Cañete
1   Department of Pediatric Oncology, Hospital Universitario y Politécnico La Fe. Valencia, Spain
,
Victoria Castel
1   Department of Pediatric Oncology, Hospital Universitario y Politécnico La Fe. Valencia, Spain
› Author Affiliations
Further Information

Publication History

03 December 2015

14 December 2015

Publication Date:
13 February 2016 (online)

    Permissions and Reprints

Abstract

Neuroblastoma is the most common extracranial solid tumor in childhood, arising in the sympathetic nervous system, metastatic in half of the patients at diagnosis, with bone and bone marrow as the most frequent sites involved. Most neuroblastomas express the noradrenalin transporter molecule and take up metaiodobenzylguanidine (mIBG), providing a sensitive and specific method of assessing primary tumor and metastatic sites (soft tissue, bone marrow, and bone) when labeled with iodine-123, both at diagnosis, for staging, and as a prognostic factor for evaluation of response to therapy, especially when a semiquantitative scoring method is used. mIBG labeled with iodine-131 has demonstrated activity for targeted therapy of neuroblastoma in both relapsed and newly diagnosed patients, and is being used in clinical trials to optimize treatment of high-risk patients.

Keywords

neuroblastoma - mIBG - treatment - scoring
 

  • References

  • 1 London WB, Castleberry RP, Matthay KK , et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 2005; 23 (27) 6459-6465
    CrossrefPubMedGoogle Scholar
  • 2 Olivier P, Colarinha P, Fettich J , et al. Guidelines for radioiodinated MIBG scintigraphy in children. Eur J Nucl Med Mol Imaging 2003; 30 (5) B45-B50
    CrossrefPubMedGoogle Scholar
  • 3 Piccardo A, Lopci E, Conte M , et al. Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. Eur J Nucl Med Mol Imaging 2012; 39 (1) 57-71
    CrossrefPubMedGoogle Scholar
  • 4 Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med 2009; 50 (8) 1237-1243
    CrossrefPubMedGoogle Scholar
  • 5 Leung A, Shapiro B, Hattner R , et al. Specificity of radioiodinated MIBG for neural crest tumors in childhood. J Nucl Med 1997; 38 (9) 1352-1357
    PubMedGoogle Scholar
  • 6 Bouvier JF, Philip T, Chauvot P , et al. Pitfalls and solutions in neuroblastoma diagnosis using radioiodine MIBG: our experience about 50 cases. Prog Clin Biol Res 1988; 271: 707-720
    PubMedGoogle Scholar
  • 7 Freitas JE. Adrenal cortical and medullary imaging. Semin Nucl Med 1995; 25 (3) 235-30
    CrossrefPubMedGoogle Scholar
  • 8 Taggart DR, Han MM, Quach A , et al. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol 2009; 27 (32) 5343-5349
    CrossrefPubMedGoogle Scholar
  • 9 Seo Y, Gustafson WC, Dannoon SF , et al. Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model. Mol Imaging Biol 2012; 14 (6) 735-742
    CrossrefPubMedGoogle Scholar
  • 10 Rufini V, Fisher GA, Shulkin BL, Sisson JC, Shapiro B. Iodine-123-MIBG imaging of neuroblastoma: utility of SPECT and delayed imaging. J Nucl Med 1996; 37 (9) 1464-1468
    PubMedGoogle Scholar
  • 11 Melzer HI, Coppenrath E, Schmid I , et al. 123I-MIBG scintigraphy/SPECT versus 18F-FDG PET in paediatric neuroblastoma. Eur J Nucl Med Mol Imaging 2011; 38 (9) 1648-1658
    CrossrefPubMedGoogle Scholar
  • 12 Matthay KK, Shulkin B, Ladenstein R , et al. Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer 2010; 102 (9) 1319-1326
    CrossrefPubMedGoogle Scholar
  • 13 Matthay KK, Edeline V, Lumbroso J , et al. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 2003; 21 (13) 2486-2491
    CrossrefPubMedGoogle Scholar
  • 14 Ady N, Zucker JM, Asselain B , et al. A new 123I-MIBG whole body scan scoring method—application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer 1995; 31A (2) 256-261
    PubMedGoogle Scholar
  • 15 Messina JA, Cheng SC, Franc BL , et al. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer 2006; 47 (7) 865-874
    CrossrefPubMedGoogle Scholar
  • 16 Yanik GA, Levine JE, Matthay KK , et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 2002; 20 (8) 2142-2149
    CrossrefPubMedGoogle Scholar
  • 17 Suc A, Lumbroso J, Rubie H , et al. Metastatic neuroblastoma in children older than one year: prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system. Cancer 1996; 77 (4) 805-811
    CrossrefPubMedGoogle Scholar
  • 18 Frappaz D, Bonneu A, Chauvot P , et al; The SFOP Group. Metaiodobenzylguanidine assessment of metastatic neuroblastoma: observer dependency and chemosensitivity evaluation. Med Pediatr Oncol 2000; 34 (4) 237-241
    CrossrefPubMedGoogle Scholar
  • 19 Frappaz D, Philip T, Chauvin F , et al. [Systematic screening for neuroblastoma]. Arch Pediatr 1995; 2 (10) 1016-1018
    PubMedGoogle Scholar
  • 20 Perel Y, Conway J, Kletzel M , et al. Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma. J Pediatr Hematol Oncol 1999; 21 (1) 13-18
    CrossrefPubMedGoogle Scholar
  • 21 Katzenstein HM, Cohn SL, Shore RM , et al. Scintigraphic response by 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma. J Clin Oncol 2004; 22 (19) 3909-3915
    CrossrefPubMedGoogle Scholar
  • 22 Ladenstein R, Philip T, Lasset C , et al. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 1998; 16 (3) 953-965
    PubMedGoogle Scholar
  • 23 Gaze MN, Wheldon TE, O'Donoghue JA , et al. Multi-modality megatherapy with [131I]meta-iodobenzylguanidine, high dose melphalan and total body irradiation with bone marrow rescue: feasibility study of a new strategy for advanced neuroblastoma. Eur J Cancer 1995; 31A (2) 252-256
    PubMedGoogle Scholar
  • 24 Vik TA, Pfluger T, Kadota R , et al. (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: results from a prospective multicenter trial. Pediatr Blood Cancer 2009; 52 (7) 784-790
    CrossrefPubMedGoogle Scholar
  • 25 Matthay KK, Tan JC, Villablanca JG , et al. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol 2006; 24 (3) 500-506
    CrossrefPubMedGoogle Scholar
  • 26 Kang TI, Brophy P, Hickeson M , et al. Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma. J Pediatr Hematol Oncol 2003; 25 (10) 769-773
    CrossrefPubMedGoogle Scholar
  • 27 Hoefnagel CA, De Kraker J, Valdés Olmos RA, Voûte PA. [131I]MIBG as a first line treatment in advanced neuroblastoma. Q J Nucl Med 1995; 39 (4) (Suppl. 01) 61-64
    PubMedGoogle Scholar
  • 28 Riad R, Kotb M, Omar W , et al. Role of 131-I MIBG therapy in the treatment of advanced neuroblastoma. J Egypt Natl Canc Inst 2009; 21 (1) 51-58
    PubMedGoogle Scholar
  • 29 Howard JP, Maris JM, Kersun LS , et al. Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma. Pediatr Blood Cancer 2005; 44 (3) 232-239
    CrossrefPubMedGoogle Scholar
  • 30 Giammarile F, Borson-Chazot F. [Neuroendocrine tumours treated with mIBG and radiolabeled peptides]. Pathol Biol (Paris) 2006; 54 (3) 130-136
    CrossrefPubMedGoogle Scholar
  • 31 Matthay KK, Quach A, Huberty J , et al. Iodine-131—metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. J Clin Oncol 2009; 27 (7) 1020-1025
    CrossrefPubMedGoogle Scholar
  • 32 Brodeur GM, Pritchard J, Berthold F , et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11 (8) 1466-1477
    CrossrefPubMedGoogle Scholar
  • 33 Monclair T, Brodeur GM, Ambros PF , et al; INRG Task Force. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009; 27 (2) 298-303
    CrossrefPubMedGoogle Scholar